Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study
<p><strong>Objective</strong> To investigate the impact of sustained low disease activity (LDA)/remission (REM) on physical function, quality of life (QoL) and structural outcomes in secukinumab-treated psoriatic arthritis (PsA) patients from the FUTURE 5 study.</p> <p>...
| Main Authors: | , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023
|
| _version_ | 1826310256010985472 |
|---|---|
| author | Coates, LC Mease, PJ Gladman, DD Navarra, S Bao, W Gaillez, C |
| author_facet | Coates, LC Mease, PJ Gladman, DD Navarra, S Bao, W Gaillez, C |
| author_sort | Coates, LC |
| collection | OXFORD |
| description | <p><strong>Objective</strong> To investigate the impact of sustained low disease activity (LDA)/remission (REM) on physical function, quality of life (QoL) and structural outcomes in secukinumab-treated psoriatic arthritis (PsA) patients from the FUTURE 5 study.</p>
<p><strong>Methods</strong> FUTURE 5 was a randomised, double-blind, placebo-controlled, parallel-group, phase 3 study in patients with active PsA. Patients were categorised according to LDA (Minimal Disease Activity, MDA/Disease Activity index for Psoriatic Arthritis, DAPSA LDA+REM) or REM (very LDA/DAPSA REM): not achieving LDA/REM, achieving it once or sustained LDA/REM ≥3 times up to week 104. Key outcomes were improvements in Health Assessment Questionnaire Disability Index and Short Form-36 Physical Component Summary Score, proportion of non-radiographic progressors and predictors of sustained LDA response.</p>
<p><strong>Results</strong> Patients were randomised (N=996) into the following treatment groups: secukinumab 300 mg (N=222), secukinumab 150 mg loading (N=220)/non-loading (N=222) and placebo (N=332). Baseline characteristics were comparable between patients with sustained DAPSA and MDA responses. By week 104, 48%–81% and 19%–36% of the secukinumab-treated patients achieved sustained LDA and REM, respectively. Numerically greater improvements in physical function and QoL were observed with sustained LDA/REM versus LDA/REM achieved once or not at all, although patients reached the established minimal clinically important difference for all composite indices. A high proportion of secukinumab-treated patients were non-structural progressors at 2 years irrespective of achieving sustained LDA/REM. Younger age, lower body mass index at baseline, reduced tender joint count and PsA pain at week 16 were key predictors of sustained LDA in secukinumab-treated patients.</p>
<p><strong>Conclusion</strong> Sustained LDA/REM was associated with improvements in physical function, QoL and inhibition of structural damage progression.</p> |
| first_indexed | 2024-03-07T07:47:43Z |
| format | Journal article |
| id | oxford-uuid:efd10da8-9c60-4c5a-ad52-535964e690e5 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:47:43Z |
| publishDate | 2023 |
| publisher | BMJ Publishing Group |
| record_format | dspace |
| spelling | oxford-uuid:efd10da8-9c60-4c5a-ad52-535964e690e52023-06-16T17:51:23ZSecukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 studyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:efd10da8-9c60-4c5a-ad52-535964e690e5EnglishSymplectic ElementsBMJ Publishing Group2023Coates, LCMease, PJGladman, DDNavarra, SBao, WGaillez, C<p><strong>Objective</strong> To investigate the impact of sustained low disease activity (LDA)/remission (REM) on physical function, quality of life (QoL) and structural outcomes in secukinumab-treated psoriatic arthritis (PsA) patients from the FUTURE 5 study.</p> <p><strong>Methods</strong> FUTURE 5 was a randomised, double-blind, placebo-controlled, parallel-group, phase 3 study in patients with active PsA. Patients were categorised according to LDA (Minimal Disease Activity, MDA/Disease Activity index for Psoriatic Arthritis, DAPSA LDA+REM) or REM (very LDA/DAPSA REM): not achieving LDA/REM, achieving it once or sustained LDA/REM ≥3 times up to week 104. Key outcomes were improvements in Health Assessment Questionnaire Disability Index and Short Form-36 Physical Component Summary Score, proportion of non-radiographic progressors and predictors of sustained LDA response.</p> <p><strong>Results</strong> Patients were randomised (N=996) into the following treatment groups: secukinumab 300 mg (N=222), secukinumab 150 mg loading (N=220)/non-loading (N=222) and placebo (N=332). Baseline characteristics were comparable between patients with sustained DAPSA and MDA responses. By week 104, 48%–81% and 19%–36% of the secukinumab-treated patients achieved sustained LDA and REM, respectively. Numerically greater improvements in physical function and QoL were observed with sustained LDA/REM versus LDA/REM achieved once or not at all, although patients reached the established minimal clinically important difference for all composite indices. A high proportion of secukinumab-treated patients were non-structural progressors at 2 years irrespective of achieving sustained LDA/REM. Younger age, lower body mass index at baseline, reduced tender joint count and PsA pain at week 16 were key predictors of sustained LDA in secukinumab-treated patients.</p> <p><strong>Conclusion</strong> Sustained LDA/REM was associated with improvements in physical function, QoL and inhibition of structural damage progression.</p> |
| spellingShingle | Coates, LC Mease, PJ Gladman, DD Navarra, S Bao, W Gaillez, C Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study |
| title | Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study |
| title_full | Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study |
| title_fullStr | Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study |
| title_full_unstemmed | Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study |
| title_short | Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study |
| title_sort | secukinumab improves physical function and quality of life and inhibits structural damage in patients with psa with sustained remission or low disease activity results from the 2 year phase 3 future 5 study |
| work_keys_str_mv | AT coateslc secukinumabimprovesphysicalfunctionandqualityoflifeandinhibitsstructuraldamageinpatientswithpsawithsustainedremissionorlowdiseaseactivityresultsfromthe2yearphase3future5study AT measepj secukinumabimprovesphysicalfunctionandqualityoflifeandinhibitsstructuraldamageinpatientswithpsawithsustainedremissionorlowdiseaseactivityresultsfromthe2yearphase3future5study AT gladmandd secukinumabimprovesphysicalfunctionandqualityoflifeandinhibitsstructuraldamageinpatientswithpsawithsustainedremissionorlowdiseaseactivityresultsfromthe2yearphase3future5study AT navarras secukinumabimprovesphysicalfunctionandqualityoflifeandinhibitsstructuraldamageinpatientswithpsawithsustainedremissionorlowdiseaseactivityresultsfromthe2yearphase3future5study AT baow secukinumabimprovesphysicalfunctionandqualityoflifeandinhibitsstructuraldamageinpatientswithpsawithsustainedremissionorlowdiseaseactivityresultsfromthe2yearphase3future5study AT gaillezc secukinumabimprovesphysicalfunctionandqualityoflifeandinhibitsstructuraldamageinpatientswithpsawithsustainedremissionorlowdiseaseactivityresultsfromthe2yearphase3future5study |